Marlio Charles Mosseri Acquires 2,650 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri bought 2,650 shares of the firm’s stock in a transaction on Thursday, May 8th. The stock was purchased at an average cost of $8.65 per share, for a total transaction of $22,922.50. Following the completion of the acquisition, the insider now owns 2,911,532 shares in the company, valued at approximately $25,184,751.80. This trade represents a 0.09 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Tuesday, May 6th, Marlio Charles Mosseri acquired 12,444 shares of Nuvectis Pharma stock. The stock was purchased at an average cost of $8.59 per share, for a total transaction of $106,893.96.

Nuvectis Pharma Price Performance

Shares of NASDAQ:NVCT opened at $8.99 on Friday. The firm has a 50 day simple moving average of $8.99 and a 200 day simple moving average of $7.22. The company has a market cap of $212.48 million, a price-to-earnings ratio of -7.75 and a beta of -0.11. Nuvectis Pharma, Inc. has a one year low of $4.44 and a one year high of $11.80.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.03. As a group, analysts expect that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Analysts Set New Price Targets

NVCT has been the subject of several recent analyst reports. Maxim Group started coverage on Nuvectis Pharma in a research note on Wednesday, April 2nd. They set a “buy” rating and a $17.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $15.00 price target (up previously from $11.00) on shares of Nuvectis Pharma in a report on Wednesday, April 30th. Finally, Laidlaw assumed coverage on Nuvectis Pharma in a research note on Monday, March 17th. They issued a “buy” rating and a $19.00 price objective on the stock.

Hedge Funds Weigh In On Nuvectis Pharma

Several large investors have recently bought and sold shares of the company. Baldwin Wealth Partners LLC MA increased its stake in shares of Nuvectis Pharma by 0.7% in the first quarter. Baldwin Wealth Partners LLC MA now owns 358,461 shares of the company’s stock valued at $3,502,000 after buying an additional 2,500 shares during the period. Baxter Bros Inc. increased its position in Nuvectis Pharma by 20.0% in the 4th quarter. Baxter Bros Inc. now owns 15,000 shares of the company’s stock valued at $81,000 after acquiring an additional 2,500 shares during the period. Nations Financial Group Inc. IA ADV increased its position in Nuvectis Pharma by 35.0% in the 4th quarter. Nations Financial Group Inc. IA ADV now owns 13,500 shares of the company’s stock valued at $73,000 after acquiring an additional 3,500 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Nuvectis Pharma during the fourth quarter worth $34,000. Finally, Blue Zone Wealth Advisors LLC acquired a new position in shares of Nuvectis Pharma during the first quarter worth $102,000. 96.77% of the stock is currently owned by institutional investors.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.